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ncreasing evidence demonstrates that protein kinase C
 
 
 
II (PKC
 
 
 
II) promotes colon carcinogenesis. We previously
reported that colonic PKC
 
 
 
II is induced during colon
carcinogenesis in rodents and humans, and that elevated
expression of PKC
 
 
 
II in the colon of transgenic mice en-
hances colon carcinogenesis. Here, we demonstrate that
PKC
 
 
 
II represses transforming growth factor 
 
 
 
 receptor
 
type II (TGF
 
 
 
RII) expression and reduces sensitivity to TGF-
 
 
 
–
mediated growth inhibition in intestinal epithelial cells.
Transgenic PKC
 
 
 
II mice exhibit hyperproliferation, enhanced
Î
 
colon carcinogenesis, and marked repression of TGF
 
 
 
RII
expression. Chemopreventive dietary 
 
 
 
-3 fatty acids inhibit
colonic PKC
 
 
 
II activity in vivo and block PKC
 
 
 
II-mediated
hyperproliferation, enhanced carcinogenesis, and repression
of TGF
 
 
 
RII expression in the colonic epithelium of trans-
genic PKC
 
 
 
II mice. These data indicate that dietary 
 
 
 
-3
fatty acids prevent colon cancer, at least in part, through
inhibition of colonic PKC
 
 
 
II signaling and restoration of
TGF-
 
 
 
 responsiveness.
 
Introduction
 
Epidemiological studies have shown a convincing link between
dietary fat intake and colon cancer risk (for review see
Bartsch et al., 1999). Consumption of fish oil, which
contains a high level of 
 
 
 
-3 polyunsaturated fatty acids,
particularly eicosapentaenoic acid (c20:5, n-3) and doco-
sahexaenoic acid (c22:6, n-3), is associated with reduced co-
lon cancer incidence (Bang et al., 1976; Caygill and
Hill, 1995; Caygill et al., 1996). Biochemical studies
confirm that 
 
 
 
-3 fatty acids have potent chemopreventive
effects on carcinogen-induced colon cancer in rodents
(Deschner et al., 1990; Reddy et al., 1991; Chang et al.,
1997). Despite the compelling epidemiological and bio-
chemical evidence demonstrating the efficacy of 
 
 
 
-3 fatty
acids in colon cancer chemoprevention (Rose and Connolly,
1999), little is known about how these dietary lipids mediate
their protective effects. 
 
 
 
-3 fatty acids can inhibit the colonic
epithelial hyperproliferation observed during colon carcino-
genesis, suggesting that proliferative signaling is an important
target of their chemopreventive effects (Anti et al., 1994,
1997; Latham et al., 1999).
Elevated colonic protein kinase C 
 
 
 
II (PKC
 
 
 
II)* expression
and activity correlate with colon carcinogenesis in both rodents
and humans (Murray et al., 1999; Gokmen-Polar et al., 2001).
Elevated PKC
 
 
 
II expression in the colonic epithelium of
transgenic mice induces hyperproliferation and enhances
susceptibility to azoxymethane (AOM)-induced colon carcino-
genesis (Murray et al., 1999), demonstrating a direct role for
PKC
 
 
 
II in colon carcinogenesis. Based on these data, we
hypothesized that 
 
 
 
-3 fatty acids block colon carcinogenesis by
interfering with proliferation via inhibition of PKC
 
 
 
II sig-
naling. To test this hypothesis, we evaluated the effect of a diet
high in 
 
 
 
-3 fatty acids on colonic PKC
 
 
 
II activity and sig-
naling. Dietary 
 
 
 
-3 fatty acids inhibited PKC
 
 
 
II activity and
suppressed PKC
 
 
 
II-mediated hyperproliferation and colon
carcinogenesis in vivo. In addition, our data demonstrate that
PKC
 
 
 
II represses transforming growth factor 
 
 
 
 receptor type II
(TGF
 
 
 
RII) expression in vitro and in vivo, and that this
repression is reversed by dietary 
 
 
 
-3 fatty acids.
 
Address correspondence to Alan P. Fields, Sealy Center for Cancer Cell
Biology, University of Texas Medical Branch, 301 University Blvd.,
Galveston, TX 77555-1048. Tel.: (409) 747-1935. Fax: (409) 747-1938.
E-mail: afields@utmb.edu
Key words: protein kinase C; colon carcinogenesis; 
 
 
 
-3 fatty acids; trans-
forming growth factor 
 
 
 
; hyperproliferation
 
*Abbreviations used in this paper: ACF, aberrant crypt foci; AOM,
azoxymethane; BrdU, bromodeoxyuridine; PKC
 
 
 
II, protein kinase C
 
 
 
II; RIE, rat intestinal epithelial; TGF
 
 
 
RII, transforming growth factor
 
 
 
 receptor type II. 
916 The Journal of Cell Biology 
 
|
 
 
 
Volume 157, Number 6, 2002
 
Results and discussion
 
PKC
 
 
 
II is a lipid-dependent protein kinase whose activity
can be modulated in vitro by 
 
 
 
-3 fatty acids (Holian and
Nelson, 1992; Davidson et al., 2000; Seung Kim et al.,
2001). Therefore, we assessed the relationship between co-
lonic PKC
 
 
 
II activity and dietary 
 
 
 
-3 fatty acids during
AOM-induced colon carcinogenesis in vivo. Cytosolic and
membrane extracts from colonic epithelia of male Sprague-
Dawley rats fed an 
 
 
 
-6 fatty acid diet (15% maize oil by
weight) or 
 
 
 
-3 fatty acid diet (3.5% maize oil, 11.5% fish
oil) were subjected to immunoblot analysis for PKC
 
 
 
II (Fig.
1). A significant decrease in the level of membrane-associ-
ated PKC
 
 
 
II was observed in the colonic epithelium of ani-
mals fed 
 
 
 
-3 fatty acids, whereas cytosolic PKC
 
 
 
II levels
were similar in both diet groups. The membrane association
of conventional PKC isozymes, including PKC
 
 
 
II, is widely
accepted as an indirect measure of PKC enzyme activation
in vivo
 
, 
 
because it is not technically feasible to directly deter-
mine the activity of the enzyme in situ. Our results are con-
sistent with the direct inhibition of PKC
 
 
 
II activity by 
 
 
 
-3
fatty acids in vitro (Holian and Nelson, 1992).
We previously characterized transgenic mice expressing ele-
vated levels of PKC
 
 
 
II in the colonic epithelium similar to
those observed in mouse colon tumors (Murray et al., 1999;
Gokmen-Polar et al., 2001). Transgenic PKC
 
 
 
II mice exhibit
a hyperproliferative phenotype and enhanced colon carcino-
genesis (Murray et al., 1999). Therefore, we assessed the effect
of dietary 
 
 
 
-3 fatty acids on AOM-mediated carcinogenesis in
transgenic PKC
 
 
 
II mice. Transgenic PKC
 
 
 
II mice fed a diet
rich in 
 
 
 
-6 fatty acids exhibited enhanced colon carcinogene-
sis, as evidenced by increased numbers of preneoplastic le-
sions, aberrant crypt foci (ACF) (Fig. 2 A). In contrast, a diet
rich in 
 
 
 
-3 fatty acids inhibited the enhanced colon carcino-
genesis characteristic of transgenic PKC
 
 
 
II mice. Thus, di-
etary 
 
 
 
-3 fatty acids block PKC
 
 
 
II activation and attenuate
the procarcinogenic effects of PKC
 
 
 
II in the colon in vivo.
Transgenic PKC
 
 
 
II mice exhibit hyperproliferation of
the colonic epithelium (Murray et al., 1999), whereas di-
etary 
 
 
 
-3 fatty acids suppress carcinogen-induced hyper-
proliferation (Latham et al., 1999). Therefore, we assessed
the effect of dietary 
 
 
 
-3 fatty acids on the hyperproliferative
phenotype of transgenic PKC
 
 
 
II mice (Fig. 2 B). Whereas
transgenic PKC
 
 
 
II mice exhibited hyperproliferation when
fed an 
 
 
 
-6 fatty acid diet, an 
 
 
 
-3 fatty acid diet selectively
suppressed this hyperproliferative phenotype (Fig. 2 B).
These data demonstrate that dietary 
 
 
 
-3 fatty acids sup-
press the hyperproliferative phenotype observed in trans-
genic PKC
 
 
 
II mice and provide a plausible mechanism for
the chemopreventive effects of dietary 
 
 
 
-3 fatty acids on
PKC
 
 
 
II-mediated colon carcinogenesis.
To gain insight into how PKC
 
 
 
II enhances colon car-
cinogenesis, we established rat intestinal epithelial (RIE)-1
cells that stably express PKC
 
 
 
II (Fig. 3). Parental RIE-1
cells, which, like most cells of the intestinal epithelium, ex-
press little or no PKC
 
 
 
II, were infected with a retrovirus
containing the full-length human PKC
 
 
 
II cDNA (Fig. 3
A). Comparative gene microarray analysis of RIE-1 and
RIE/PKC
 
 
 
II cells was used to identify potential targets for
PKC
 
 
 
II. Among the genes identified through this analysis,
TGF
 
 
 
RII expression was found to be markedly repressed
Figure 1. Dietary  -3 fatty acids block AOM-induced PKC II 
activity. PKC II expression was assessed in membrane and cytosolic 
fractions from colonic epithelial cell extracts from the distal colon of 
AOM-treated Sprague-Dawley rats fed either an  -6 or an  -3 fatty 
acid diet. Values represent means   SEM, n   5.
Figure 2. Dietary  -3 fatty acids block PKC II-enhanced colon 
carcinogenesis and colonic hyperproliferation. (A) Effect of dietary 
fat intake on AOM-induced ACF formation in transgenic PKC II 
mice. Mice were terminated 12 wk after the final AOM injection 
and the colons analyzed for ACF formation as described previously 
(McLellan et al., 1991; Murray et al., 1999). Values represent
means   SEM, n   6–18 animals/experimental group. (B) Mice 
were fed an  -6 or  -3 diet for 18 d. 1 h before sacrifice, mice were 
injected with 50 mg/kg BrdU and distal colon was isolated, fixed in 
4% paraformaldehyde, and analyzed for proliferation as determined 
by BrdU labeling (Chang et al., 1997). Results respresent prolifera-
tive index relative to nontransgenic controls. Values represent 
means   SEM, n   4–5 animals/experimental group.  -3 fatty acids inhibit PKC II signaling | Murray et al. 917
in RIE/PKC II cells, when compared with RIE-1 cells.
These results were confirmed by Western blotting using a
specific antibody to TGF RII (Fig. 3 A). Given the im-
portance of TGF-  signaling in colonic epithelial cell pro-
liferation and differentiation, and the frequent loss of
TGF-  responsiveness during colon carcinogenesis (Mar-
kowitz and Roberts, 1996), we assessed whether this
change in TGF RII expression leads to an alteration in the
well-documented response of the RIE-1 cells to TGF- 
(Ko et al., 1995). RIE-1 and RIE/PKC II cells were trans-
fected with a reporter plasmid containing a TGF- –
responsive element from the tissue plasminogen activator
promoter linked to luciferase (Wrana et al., 1992). RIE-1
cells respond to TGF-  by activation of this TGF- –
dependent reporter construct (Fig. 3 B). However, RIE/
PKC II cells showed a diminished transcriptional response
to TGF-  consistent with repression of TGF RII expres-
sion. Cotransfection of the TGF-  reporter plasmid with a
plasmid containing R4TD202, a constitutively active mu-
tant of TGF RI (Feng and Derynck, 1996), resulted in
comparable increases in transcriptional activity in both
RIE-1 and RIE/PKC II cells (Fig. 3 B), indicating that
signaling downstream of the TGF-  receptor is intact in
both RIE-1 and RIE/PKC II cells. Consistent with the
transcriptional response to TGF- , RIE-1 cell proliferation
was inhibited by TGF-  as determined by a reduction in
the number of bromodeoxyuridine (BrdU)-labeled cells af-
ter addition of TGF- 1 to mid-log phase cultures (Fig. 3
C). RIE/PKC II cells, however, were relatively insensitive
to TGF-  inhibition of BrdU labeling (Fig. 3 C). Al-
though there was no detectable growth phenotype associ-
ated with expression of PKC II in the absence of added
TGF-  (Fig. 3 D), RIE/PKC II cells were much less sensi-
tive to TGF- –mediated inhibition of proliferation (Fig.
3 E). Thus, expression of PKC II leads to repression of
TGF RII and loss of TGF-  responsiveness in RIE-1 cells.
To directly demonstrate that PKC II activity is responsi-
ble for repression of TGF RII protein expression in RIE/
PKC II cells, we determined the effect of the PKC -selec-
tive inhibitor LY379196 on TGF RII expression. Treat-
ment of RIE/PKC II cells with increasing concentrations of
LY379196 led to a dose-dependent increase in TGF RII
protein expression (Fig. 4 A). Quantitative analysis of these
expression data (Fig. 4 B) indicate an apparent ED50 for re-
expression of TGF RII of  40 nM LY379196, consistent
with the reported IC50 of LY379196 for PKC II of 30 nM
(Jirousek et al., 1996). It should also be noted that re-expres-
sion of TGF RII is accompanied by reduced electrophoretic
mobility of TGF RII upon SDS-PAGE. Because TGF RII
is highly glycosylated, it is possible that this shift reflects
changes in posttranslational processing of the protein. The
significance of this observation to TGF- –mediated signal-
ing is unclear. Nevertheless, these data provide direct evi-
dence that PKC II activity is responsible for repression of
TGF RII in these cells.
TGF-  is a potent growth inhibitor in epithelial cells
(Lamprecht et al., 1989) and the loss of TGF-  responsive-
ness is a common feature of many human colon cancers,
particularly those exhibiting the microsatellite instability
phenotype (Markowitz et al., 1995). Loss of TGF-  respon-
siveness in hereditary nonpolyposis colon cancer syndrome
is due to inactivating mutations within TGF RII (Marko-
witz et al., 1995; Kim et al., 2000). Recent studies indicate
that transcriptional repression of TGF RII expression is a
common mechanism for loss of TGF-  responsiveness in
Figure 3. Characterization of TGF-  signaling in RIE/PKC II cells. 
(A) Expression of PKC II, TGF RII, and actin in RIE-1 and RIE/
PKC II cells. RIE-1 cells were infected with pBABEpuro containing 
full-length human PKC II or empty pBABEpuro vector. Puromycin-
resistant cell populations were isolated and screened for expression 
of PKC II, TGF RII, and actin by immunoblotting. (B) Effect of 
PKC II expression on TGF- –induced transcription in RIE-1 cells. 
RIE-1 and RIE/PKC II cells were transiently transfected with 0.4  g 
of 3TP/luc TGF-  reporter plasmid plus 1  g of TK/renilla as an 
internal control for transfection efficiency. TGF- 1 (3 ng/ml) was 
added to cells as indicated. Cellular extracts were prepared after
24 h of TGF-  exposure and assayed for firefly and renilla luciferase 
activity. In addition, some cells were cotransfected with an 
expression vector encoding constitutively active TGF-  chimeric 
receptor R4TD202. Data represent the mean   SD from three 
independent experiments measuring firefly luciferase activity 
normalized to renilla luciferase activity. (C) Effect of PKC II expression 
on TGF- –mediated inhibition of BrdU incorporation in RIE-1 cells. 
TGF-  responsiveness of RIE-1 and RIE/PKC II cells was assayed by 
measuring inhibition of BrdU incorporation. (D) Effect of PKC II 
expression on RIE-1 cell proliferation. Growth of RIE-1 and RIE/
PKC II cells in growth medium in the absence of TGF-  was 
measured by hemocytometer count on a daily basis. Data represent the 
mean   SD from three dishes. (E) Effect of PKC II expression on 
TGF- –mediated inhibition of RIE-1 cell proliferation. Cultures of 
RIE-1 and RIE/PKC II cells were treated with 3 ng/ml TGF- 1, and 
cell growth was monitored by measuring OD570 after reduction of 
MTT. Data represent the mean   SD from three wells.918 The Journal of Cell Biology | Volume 157, Number 6, 2002
many tumor types, including colon cancers (Kim et al.,
2000). Our data demonstrate that PKC II represses TGF-
 RII expression in RIE-1 cells, and indicate that PKC II-
mediated loss of TGF-  responsiveness is involved in the
hyperproliferative and procarcinogenic effects of PKC II in
the colonic epithelium. Therefore, we assessed whether
TGF RII is a target for colonic PKC II in vivo (Fig. 5).
Colonic epithelial cell extracts from transgenic PKC II and
nontransgenic mice fed an  -6 fatty acid diet were subjected
to immunoblot (Fig. 5 A) and immunofluorescence analysis
(Fig. 5 B, 1 and 4) using a specific TGF RII antibody. Ex-
tracts from nontransgenic mice contained little PKC II, but
abundant TGF RII, whereas those from transgenic PKC II
mice contained elevated PKC II and a reduced level of
TGF RII (Fig. 5 A). Immunofluorescence analysis for
TGF RII confirmed these immunoblotting results (Fig. 5
B). Colonic crypts from nontransgenic mice fed an  -6 fatty
acid diet (Fig. 5 B, 4) exhibited abundant staining for TGF-
 RII. Staining was strongest in the upper third and along
the luminal surfaces of the colonic crypts, consistent with
the reported distribution of TGF RII in the colonic epithe-
lium (Guda et al., 2001). In contrast, colonic crypts from
transgenic PKC II mice fed an  -6 fatty acid diet (Fig. 5 B,
1) expressed much lower levels of TGF RII, confirming
that TGF RII expression was repressed by PKC II in the
colonic epithelium in vivo.
Because PKC II mediates repression of TGF RII ex-
pression and dietary  -3 fatty acids inhibit PKC II signal-
ing, we predicted that dietary  -3 fatty acids would restore
TGF RII expression in transgenic PKC II mice. Indeed,
transgenic PKC II mice fed an  -3 fatty acid diet showed
levels of TGF RII comparable to those seen in nontrans-
genic mice (Fig. 5 B, 2). Therefore, TGF RII is a critical
gene target of PKC II-mediated repression in RIE-1 cells
in vitro and in the colonic epithelium in vivo. Our data are
consistent with the conclusion that PKC II down-regu-
lates TGF RII expression, thereby inducing a TGF- –
insensitive state. Because TGF-  inhibits proliferation and
promotes differentiation of intestinal epithelial cells (Lam-
precht et al., 1989), PKC II-mediated repression of TGF-
 RII imposes a hyperproliferative state that increases sensi-
tivity to carcinogens, such as AOM. Dietary  -3 fatty acids
inhibit PKC II activity and restore TGF RII expression
in the colonic epithelium of transgenic PKC II mice, re-
sulting in reversal of the hyperproliferative phenotype and
attenuation of the enhanced colon carcinogenesis charac-
teristic of transgenic PKC II mice.
Figure 4. The selective PKC  inhibitor LY379196 restores 
TGF RII expression in RIE/PKC II cells. (A) RIE/PKC II cells were 
treated with the indicated concentration of LY379196 for 48 h, and 
total cellular protein extracts were subjected to immunoblot analysis 
for TGF RII expression. (B) Quantitative analysis of the immunoblot 
data shown in A.
Figure 5.  -3 fatty acids restore colonic 
TGF RII expression in PKC II mice. 
(A) Immunoblot analysis of TGF RII 
expression. PKC II transgenic mice and 
nontransgenic littermates were killed, the 
colonic epithelia were scraped, and 150 
 g of the resulting protein extract was 
subjected to immunoblot analysis using 
antibody specific for TGF RII, PKC II, or 
actin (Santa Cruz Biotechnology, Inc.).
(B) Immunofluorescence analysis of TGF-
 RII expression. PKC II transgenic mice 
(1, 2, and 3) and nontransgenic littermates 
(4, 5, and 6) were fed (ad libitum) either 
an  -3– (2, 3, 5, and 6) or  -6– (1 and 4) 
containing diet beginning at 6 wk of 
age. After 18 d, mice were killed and 
distal colons were subjected to 
immunofluorescence analysis using a 
specific antibody to TGF RII (1,2, 4, 
and 5) or secondary antibody only (3 and 
6). All panels are at 400  magnification.  -3 fatty acids inhibit PKC II signaling | Murray et al. 919
Our results provide a plausible link between chemopre-
ventive dietary  -3 fatty acids, colonic PKC II activity,
TGF-  signaling, cellular proliferation, and susceptibility to
colon cancer. Therefore colonic PKC II, which is induced
early during colon carcinogenesis, represents a novel and po-
tentially highly effective target for chemopreventive therapy
in colon cancer. Given the strong association of dietary  -3
fatty acids with the chemoprevention of other epithelial can-
cers, including breast and prostate cancer (Rose and Con-
nolly, 1999), as well as neurological conditions such as bipo-
lar disorder (Seung Kim et al., 2001), it is possible that
selective PKC II inhibition could prove to be an important
therapeutic modality in the treatment and chemoprevention
of multiple epithelial cancers and central nervous system dis-
orders. Likewise, because repression of TGF RII expression
has been documented in many cancer cell types, including
gastric cancer, colon cancer, small cell lung cancer, esoph-
ageal cancer, hepatocellular carcinoma, squamous cell carci-
noma, breast cancer, endometrial cancer, bladder cancer,
and osteosarcoma (for review see Kim et al., 2000), it is pos-
sible that PKC II inhibition, either through dietary modu-
lation or pharmacological intervention, may be of therapeu-
tic value for a broad range of major cancer types by restoring
TGF-  responsiveness in these tumors.
Materials and methods
Production and maintenance of transgenic mice
Transgenic PKC II mice were generated and maintained essentially as de-
scribed previously (Murray et al., 1999), except that the transgene con-
struct used a modified version of the rat liver fatty acid binding protein pro-
moter containing four copies of a heptad repeat enhancer region that
directs enhanced and more sustained expression in the entire colonic epi-
thelium (Simon et al., 1997).
Cell fractionation and PKC II immunoblot analysis
3-wk-old Sprague-Dawley rats fed either an  -6 fatty acid diet (15% maize
oil by weight) or an  -3 fatty acid diet (3.5% maize oil, 11.5% fish oil, by
weight; Chang et al., 1997). After 1 wk on experimental diets, rats were in-
jected with AOM (Chang et al., 1997). Animals were terminated at 16 wk af-
ter AOM injection. Colonic epithelial cell extracts from the distal colon were
fractionated into membrane and cytosolic fractions and subjected to immu-
noblot analysis for PKC II expression (Davidson et al., 2000). Band intensity
was quantitated using the Bio-Rad Laboratories Fluor-s imaging system.
ACF analysis
6–8-wk-old transgenic PKC II mice and nontransgenic littermates were
maintained on either an  -6 or  -3 fatty acid diet (ad libitum) until termi-
nation of the experiment. 1 wk after introduction of the diet, mice received
intraperitoneal injections of 10 mg/kg AOM 1 /wk for 4 wk. Mice were
terminated 12 wk after the final AOM injection and the colons were ana-
lyzed for ACF formation (McLellan et al., 1991; Murray et al., 1999).
Colonic epithelial cell proliferation analysis
6–8-wk-old transgenic PKC II mice and nontransgenic littermates were
maintained on an  -6 or  -3 fatty acid diet for 18 d. 1 h before sacrifice,
mice were injected with 50 mg/kg BrdU. Distal colon was isolated, fixed
in 4% paraformaldehyde, and analyzed for proliferation as determined by
BrdU labeling (Chang et al., 1997).
TGF-  transcriptional response assay
RIE-1 and RIE/PKC II cells were transiently transfected with 0.4  g of 3TP/
luc TGF-  reporter plasmid (Wrana et al., 1992) plus 1  g of vector ex-
pressing renilla luciferase under control of the thymidine kinase promoter
as an internal control for transfection efficiency. TGF- 1 (3 ng/ml) was
added to cells. After 24 h of TGF-  exposure, cellular extracts were pre-
pared and assayed for firefly and renilla luciferase activity. Data are pre-
sented as firefly luciferase corrected for the level of renilla luciferase. Some
cells were cotransfected with 0.1  g of an expression vector encoding con-
stitutively active TGF-  chimeric receptor R4TD202 (Feng and Derynck,
1996) and assayed for TGF-  reporter activity as described above.
Effect of PKC II on RIE-1 cell proliferation and 
TGF-  responsiveness
TGF-  responsiveness of RIE-1 and RIE/PKC II cells was assayed by mea-
suring inhibition of BrdU incorporation. Midlog phase cells were treated
with 3 ng/ml TGF-  for 24 h followed by 1 mM BrdU for 30 min. Cells were
then permeabilized and stained with anti-BrdU antibody using the BD
PharMingen BrdU FlowKit
®, according to the manufacturer’s recommenda-
tions. Approximately 15,000 cells from each culture were analyzed using a
Becton Dickinson flow cytometer. RIE-1 and RIE/PKC II cells were plated
at  10
5 cells per 6-cm dish. At 24-h intervals, three dishes from each line
were harvested by trypsinization and the cells were counted using a
hemocytometer. RIE-1 and RIE/PKC II cells were plated in 96-well plates at
2   10
4 cells in 0.2 ml of medium   3 ng/ml TGF- 1. At 24-h intervals, cell
growth was assayed in triplicate wells by measuring OD570 after reduction
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT).
Analysis of TGF-  RII expression
Equal amounts of cell lysates from RIE-1 and RIE/PKC II cells were sub-
jected to immunoblot analysis using antibody specific for TGF RII,
PKC II, or actin (Santa Cruz Biotechnology, Inc.). PKC II transgenic mice
and nontransgenic littermates were killed, the colonic epithelia were
scraped, and 150  g of the resulting protein extract was subjected to im-
munoblot analysis using the same antibodies listed above. Immunoblot im-
ages were captured using a Stratagene Eagle Eye imager. To assess the ef-
fect of PKC II inhibition on TGF RII protein expression, confluent cultures
of RIE/PKC II cells were placed in medium containing 0.2% FBS plus the
concentrations of LY379196 indicated in the figure legend. All cultures
contained 0.1% DMSO as a diluent control. After 2 d, total cellular protein
was extracted and 50  g of protein per lane was subjected to immunoblot
analysis for TGF RII expression. Chemiluminescent exposure was adjusted
to conform to a linear response range, and data were quantified using a
Lynx digital image processor.
Immunofluorescence analysis of TGF RII expression
6-wk-old PKC II transgenic mice and nontransgenic littermates were fed
either an  -3– or  -6–containing diet ad libitum. After 18 d on the defined
diets, the mice were killed. Distal colon was isolated, fixed in 4%
paraformaldehyde, sectioned, and subjected to immunofluorescence anal-
ysis for TGF RII expression. Images were captured using a CCD color dig-
ital camera and digital image capture software.
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